enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Michael Heffernan has assumed the role of Chairman of enGene’s Board, succeeding Dr. Richard Glickman who stepped down after more than 14 years to support the company's transition to commercialization. The company confirmed its regulatory timeline, planning a pre-BLA meeting and initiating BLA submission for detalimogene in the second half of 2026 with potential FDA approval in 2027.
Key figures
- Glickman tenure years
- over 14
- Pivotal cohort patients
- 125
- Heffernan experience years
- over 30
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.